EXTON, Pa., June 8 /PRNewswire/ -- Morphotek, Inc. today announced initiation of Phase II efficacy studies in major cancer centers worldwide for its anti-cancer antibody MORAb-003. MORAb-003 is a monoclonal antibody that targets the folate receptor alpha (FRA), a target over-expressed in over 90% of ovarian cancers and a number of other solid tumors. The antibody works via suppression of FRA-mediated signal transduction and induces tumor-specific cytotoxicity by both antibody dependent cellular and complement mediated immune-effector mechanisms. The antibody has shown clinical activity in a Phase I trial which was presented by investigators from the Memorial Sloan-Kettering Cancer Center at the American Society of Clinical Oncology Meeting on June 4th, 2006.
